When the MS patients were grouped according to OCB status, there was a trend toward decreased TIGIT expression in OCB-positive patients (0.48 FC) compared to OCB-negative patients (0.70 FC) (P = 0.06, Figure 1B). The gene discussed is TIGIT; the disease is myeloid sarcoma.